Department of Gastroenterology, Cleveland Clinic Florida, Weston, Florida, USA.
Department of Pathology, Cleveland Clinic Florida, Weston, Florida, USA.
JPEN J Parenter Enteral Nutr. 2018 Mar;42(3):658-660. doi: 10.1177/0148607117718480. Epub 2017 Dec 13.
Teduglutide (TG) is approved for the treatment of parenteral nutrition (PN)-dependent adult patients with short bowel syndrome (SBS). Its well-known adverse effect is expedited growth of colon polyps and potential formation of new polyps. Apart from animal studies, de novo development of duodenal polyps in a patient during TG therapy has not been reported in the literature. We report a case of a 71-year-old man with SBS on TG who developed multiple new duodenal polyps that were found incidentally during a diagnostic endoscopy. Furthermore, an accelerated growth of duodenal polyps was noted while on TG therapy, suggesting a potential trophic effect of TG on these polyps. There are no current recommendations for the surveillance of intestinal polyps in patients on TG therapy, but we recommend exercising caution and possible need for surveillance based on this case report.
特迪格鲁肽（TG）获批用于治疗依赖肠外营养（PN）的成人短肠综合征（SBS）患者。其众所周知的不良反应是加速结肠息肉的生长，并可能形成新的息肉。除了动物研究外，在 TG 治疗期间患者发生十二指肠新息肉的情况在文献中尚未报道。我们报告了一例 SBS 患者在接受 TG 治疗时发生多发性新的十二指肠息肉，这些息肉是在诊断性内镜检查中偶然发现的。此外，在接受 TG 治疗期间，观察到十二指肠息肉的生长加速，表明 TG 对这些息肉可能具有营养作用。目前尚无关于 TG 治疗患者肠息肉监测的建议，但基于本病例报告，我们建议谨慎对待，并可能需要进行监测。
